Juan Lama

Juan Lama, watching the virus world from the bench to the outbreak map

Juan Lama’s public Scoop.it presence is concentrated, specialized and unmistakably scientific. Under the RetroVirox identity, he tracks the virus world through one large active topic that blends antiviral development, vaccine progress, outbreak intelligence and basic virology for a global readership.

A CRO lens on virus science

The bio places Juan Lama inside RetroVirox, a contract research organization focused exclusively on virology. That background shows in the selection: drug assays, vaccine candidates and clinically relevant findings receive consistent attention.

Quiet, precise editorial judgment

The editorial voice is mostly silent, but not neutral in its choices. It favors papers, milestone discoveries, outbreak declarations and credible health reporting over opinion-driven material.

Pathogens as a connected map

The topic moves easily between COVID-19, influenza, Ebola, hepatitis B, HIV, hantavirus, mpox and emerging zoonoses. That range reflects a virologist’s habit of seeing pathogens as a connected system of risks, tools and countermeasures.

What defines this selection

Daily-scale vigilance

With 3,200 posts in a single active topic, Juan Lama has built a dense record of viral science and outbreak news. The scale matters because the field moves fast; the value is in sustained watching rather than occasional commentary.

Evidence before noise

The source mix leans toward journals, institutions and major newsrooms: Nature, Science, NEJM, WHO-linked reporting, Reuters and public-health coverage. The result is a science-forward feed that privileges evidence, trial data and documented alerts.

From mechanism to medicine

Vaccines, antivirals, diagnostics, basic mechanisms and zoonotic outbreaks appear side by side. That breadth gives the work its practical texture: readers can see both the molecular detail and the public-health consequence.

A field-facing reach

More than 415,000 views and 194,000 unique visitors point to a topic that has found an audience beyond a narrow professional circle. It serves specialists, industry readers and anyone tracking the next viral threat.

Deep dives

A virology radar tuned to both papers and outbreaks

Virus World reads like a daily scan of the places where laboratory science meets public risk. Ebola vaccine trials, Congo outbreak alerts and hantavirus travel cases sit close together, making the topic less a single-disease feed than a watchtower for viral threats as they move from journals into institutions, regulators and headlines.

The strongest through-line is translational virology. Antiviral candidates, prophylaxis studies and vaccine platforms are selected for their practical consequence: not just what a virus does, but what medicine may soon be able to do about it.

The topic also keeps an eye on frontier questions, including synthetic biology and the changing tools of discovery. Posts about AI-generated viruses or host-cell mechanisms show a willingness to follow uncomfortable, high-stakes science without turning the feed into speculation.